RQ Biotechnology Limited
RQ Biotechnology’s mission is to develop medicines based on potent broad-spectrum monoclonal antibodies to provide instant and long-lasting protection for vulnerable people at risk of severe disease or death from current and future viral infections. The company focuses on innovative antibody discovery, passive immunization, and rapid development of treatments for infectious diseases, including COVID-19, influenza, cytomegalovirus, and respiratory syncytial virus. RQ Bio collaborates with academic institutions like the University of Oxford and partners with pharmaceutical companies such as AstraZeneca to bring effective therapies to market quickly.
Industries
Nr. of Employees
small (1-50)
RQ Biotechnology Limited
Scale Space, 58 Wood Lane, London, W12 7RZ, United Kingdom
Products
Clinical-stage monoclonal antibody asset for prevention of COVID-19 (licensed)
A clinical-stage long-acting monoclonal antibody discovered through the company's discovery platform and licensed to a pharmaceutical partner for development and commercialisation as a pre-exposure prophylactic against SARS‑CoV‑2 in immunocompromised individuals.
Clinical-stage monoclonal antibody asset for prevention of COVID-19 (licensed)
A clinical-stage long-acting monoclonal antibody discovered through the company's discovery platform and licensed to a pharmaceutical partner for development and commercialisation as a pre-exposure prophylactic against SARS‑CoV‑2 in immunocompromised individuals.
Services
Discovery services focused on identifying and characterising neutralising monoclonal antibodies for infectious disease targets delivered via collaborative partnerships and licensing agreements with pharmaceutical developers.
Structuring exclusive licences and milestone/royalty arrangements and supporting partner-led clinical development and regulatory interactions.
Program and portfolio management services to prioritise and coordinate multiple discovery programmes across viral targets.
Discovery services focused on identifying and characterising neutralising monoclonal antibodies for infectious disease targets delivered via collaborative partnerships and licensing agreements with pharmaceutical developers.
Structuring exclusive licences and milestone/royalty arrangements and supporting partner-led clinical development and regulatory interactions.
Program and portfolio management services to prioritise and coordinate multiple discovery programmes across viral targets.
Expertise Areas
- Antibody discovery and engineering
- Passive immunisation for vulnerable populations
- Virology and virus evolution
- Computational biology and bioinformatics
Key Technologies
- Monoclonal antibody discovery
- Antibody engineering for long-acting therapeutics
- B cell repertoire analysis
- Computational biology pipelines
News & Updates
The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for Kavigale, an antibody discovered by RQ Bio, for COVID-19 prevention in immunocompromised individuals.
The UK IPO granted a patent for sipavibart, an antibody in AstraZeneca’s SUPERNOVA trial for COVID-19 prevention and treatment.
Dr. Ripley Ballou and Dr. Jacques Cholat joined RQ Bio's board, bringing extensive experience in vaccines and infectious diseases.
RQ Bio’s antibody AZD3152 entered clinical trials less than 12 months after discovery, and is part of AstraZeneca’s COVID-19 antibody combination.
RQ Bio was launched in May 2022 following a licensing deal with AstraZeneca, aiming to develop treatments based on broad-spectrum monoclonal antibodies.
The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for Kavigale, an antibody discovered by RQ Bio, for COVID-19 prevention in immunocompromised individuals.
The UK IPO granted a patent for sipavibart, an antibody in AstraZeneca’s SUPERNOVA trial for COVID-19 prevention and treatment.
Dr. Ripley Ballou and Dr. Jacques Cholat joined RQ Bio's board, bringing extensive experience in vaccines and infectious diseases.
RQ Bio’s antibody AZD3152 entered clinical trials less than 12 months after discovery, and is part of AstraZeneca’s COVID-19 antibody combination.
RQ Bio was launched in May 2022 following a licensing deal with AstraZeneca, aiming to develop treatments based on broad-spectrum monoclonal antibodies.